Pancreatic Ductal Adenocarcinoma (PDAC)
86
45
48
6
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
4.7%
4 terminated out of 86 trials
60.0%
-26.6% vs benchmark
7%
6 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (86)
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life
Breath Research Narrow Validation for Gastrointestinal Cancer Detection
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
EUS-Based Artificial Intelligence to Predict Outcomes in Pancreatic Cancer
A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial